AKBA

Akebia Therapeutics
AKBA

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$958.62M
EV
$1.04B
Shares Outstanding
265.99M
Beta
0.88

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$7.40
P/E 2025E
-
P/Revenue 2025E
4.81x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Akebia Therapeutics, Inc.

gainify
AKBA

Akebia Therapeutics, Inc.

AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible f...

Sector

Healthcare

Industry

Biotechnology

CEO

Butler, John

Employees

181

IPO Date

2014-03-20

Headquarters

245 First Street, Suite 1400, Cambridge, Massachusetts, 02142, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.